title: Comparison between mucinous cystic neoplasm and intraductal papillary mucinous neoplasm of the branch duct type of the pancreas with respect to expression of CD10 and cytokeratin 20.
abstract: OBJECTIVE
  Mucinous cystic neoplasm (MCN) and intraductal papillary mucinous neoplasm of the branch duct type (IPMN-BD) differ in biological and clinical behaviors, but MCN is often misdiagnosed as IPMN-BD. The purpose of this study was to find useful markers for the differential diagnosis of MCN and IPMN-BD.
  
  
  METHODS
  Immunohistochemically, the expression of the 2 types of mucin (MUC) 1 (MUC1/DF3 and MUC1/CORE), MUC2, MUC5AC, MUC6, human gastric mucin (HGM), caudal-related homeobox transcription factor 2 (CDX2), CD10, cytokeratin (CK) 7, and CK20 was examined in 7 cases of MCN and 16 cases of IPMN-BD.
  
  
  RESULTS
  Expression frequencies in MCN and IPMN-BD were 100% versus 44% for MUC1/DF3, 86% versus 31% for MUC1/CORE, 57% versus 19% for MUC2, 86% versus 100% for MUC5AC, 57% versus 88% for MUC6, 86% versus 100% for HGM, 57% versus 0% for CDX2, 71% versus 0% for CD10, 100% versus 69% for CK7, and 86% versus 6% for CK20.
  
  
  CONCLUSIONS
  Mucin 1/DF3, MUC1/CORE, CDX2, CD10, and CK20 were expressed significantly more frequently in MCN than in IPMN-BD. In particular, CD10 and CK20 showed marked differences in immunohistochemical sensitivity and specificity between MCN and IPMN-BD. It is therefore proposed that CD10 and CK20 may be used for the differential diagnosis of MCN and IPMN-BD.
authors.affiliation: Department of Pathology, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Nishigami
authors.forename: Masayuki
authors.initials: M
authors.lastname: Onodera
authors.forename: Ikuko
authors.initials: I
authors.lastname: Torii
authors.forename: Ayuko
authors.initials: A
authors.lastname: Sato
authors.forename: Li-Hua
authors.initials: LH
authors.lastname: Tao
authors.forename: Ryoji
authors.initials: R
authors.lastname: Kushima
authors.forename: Ayako
authors.initials: A
authors.lastname: Kakuno
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Kishimoto
authors.forename: Eiji
authors.initials: E
authors.lastname: Katsuyama
authors.forename: Takahiro
authors.initials: T
authors.lastname: Fujimori
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hirano
authors.forename: Makoto
authors.initials: M
authors.lastname: Satake
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Kuroda
authors.forename: Shuhei
authors.initials: S
authors.lastname: Nishiguchi
authors.forename: Jiro
authors.initials: J
authors.lastname: Fujimoto
authors.forename: Tohru
authors.initials: T
authors.lastname: Tsujimura
mesh_terms: D000368:Aged; D021441:Carcinoma, Pancreatic Ductal / Q000378:metabolism / Q000473:pathology*; D002291:Carcinoma, Papillary / Q000378:metabolism / Q000473:pathology*; D018282:Cystadenocarcinoma, Mucinous / Q000378:metabolism / Q000473:pathology*; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053554:Keratin-20 / Q000032:analysis*; D053552:Keratin-7 / Q000032:analysis; D008297:Male; D008875:Middle Aged; D055271:Mucin 5AC / Q000032:analysis; D018396:Mucin-1 / Q000032:analysis; D055262:Mucin-2 / Q000032:analysis; D055272:Mucin-6 / Q000032:analysis; D015260:Neprilysin / Q000032:analysis*; D010190:Pancreatic Neoplasms / Q000378:metabolism / Q000473:pathology*
chemical_list: D053554:Keratin-20; D053552:Keratin-7; D055271:Mucin 5AC; D018396:Mucin-1; D055262:Mucin-2; D055272:Mucin-6; D015260:Neprilysin